GSK840 is a potent and selective inhibitor of receptor-interacting protein kinase 3 (RIP3/RIPK3), used to block TNF-induced necroptosis in a concentration-dependent manner; it exhibits high-affinity binding to the RIP3 kinase domain (IC50 = 0.9 nM) and inhibits kinase activity with an IC50 of 0.3 nM; it targets a broader range of pro-necrotic stimuli than RIP1 kinase inhibitors and is applied in necroptosis-related cellular assays, such as in human HT-29 cells treated with TNF, zVAD-fmk, and SMAC mimetic.